Company research
TELA Bio, Inc.
CIK 1561921Updated Nov 14, 2026
SecurityTELA · NASDAQ · equity
TELA price & chart
Loading TradingView…
NASDAQ:TELA on TradingView ↗About the company
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient’s natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.
In the news
TELA Bio to Announce First Quarter 2026 Financial Results ↗
Recent filings
SCHEDULE 13G/A - filed by Nantahala Capital Management, LLC regarding TELA Bio, Inc.
SCHEDULE 13G/A - filed by NORTH RUN CAPITAL, LP regarding TELA Bio, Inc.
S-3 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
4 filing
Submission of Matters to a Vote of Security Holders
Items 5.07
Other Events
Items 8.01
Other Events
Items 8.01, 9.01
Entry into a Material Definitive Agreement
Items 1.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 61,587,000Source | 53,016,000Source | 59,738,000Source | 67,537,000Source | 60,204,000Source | 69,891,000Source | 77,251,000Source | 71,837,000Source | 81,418,000Source | 86,570,000Source | 78,048,000Source | 67,855,000Source |
| Property, Plant and Equipment, NetUSD | 2,213,000Source | 2,423,000Source | 2,048,000Source | 2,167,000Source | 2,349,000Source | 2,157,000Source | 2,201,000Source | 2,325,000Source | 2,226,000Source | 2,341,000Source | 1,984,000Source | 1,682,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 1,454,000Source | 1,834,000Source | 1,169,000Source | 1,549,000Source | 1,929,000Source | 1,264,000Source | 1,644,000Source | 2,024,000Source | 1,359,000Source | 1,739,000Source | 2,119,000Source | 2,499,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 29,713,000Source | 17,301,000Source | 30,424,000Source | 34,977,000Source | 26,496,000Source | 39,541,000Source | 42,833,000Source | 37,143,000Source | 50,845,000Source | 52,670,000Source | 46,729,000Source | 42,019,000Source |
| Inventory, NetUSD | 11,558,000Source | 13,600,000Source | 11,059,000Source | 11,371,000Source | 13,372,000Source | 12,213,000Source | 13,533,000Source | 13,602,000Source | 11,016,000Source | 12,781,000Source | 13,162,000Source | 11,792,000Source |
| Assets, CurrentUSD | 56,048,000Source | 44,132,000Source | 54,491,000Source | 60,745,000Source | 51,109,000Source | 64,302,000Source | 69,745,000Source | 62,618,000Source | 75,581,000Source | 78,071,000Source | 71,726,000Source | 62,447,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,503,000Source | 2,009,000Source | 3,371,000Source | 3,161,000Source | 2,144,000Source | 2,833,000Source | 2,822,000Source | 1,918,000Source | 3,373,000Source | 2,522,000Source | 2,098,000Source | 2,015,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,560,000Source | 1,796,000Source | 1,379,000Source | 1,616,000Source | 1,851,000Source | 1,442,000Source | 1,678,000Source | 1,904,000Source | 1,502,000Source | 1,738,000Source | 1,954,000Source | 1,227,000Source |
| Other Assets, NoncurrentUSD | — | 2,566,000Source | 451,000Source | 1,131,000Source | 2,701,000Source | 476,000Source | 1,626,000Source | 2,701,000Source | 500,000Source | 2,276,000Source | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 60,030,000Source | 59,288,000Source | 75,604,000Source | 58,353,000Source | 57,334,000Source | 75,092,000Source | 59,128,000Source | 57,453,000Source | 75,105,000Source | 58,112,000Source | 59,167,000Source | 53,550,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 40,000Source | 25,000Source | 45,000Source | 40,000Source | 25,000Source | 45,000Source | 40,000Source | 25,000Source | 44,000Source | 39,000Source | 24,000Source | 19,000Source |
| Additional Paid in CapitalUSD | 389,946,000Source | 343,076,000Source | 405,101,000Source | 388,968,000Source | 341,897,000Source | 404,503,000Source | 387,986,000Source | 340,812,000Source | 403,739,000Source | 387,059,000Source | 339,655,000Source | 288,361,000Source |
| Retained Earnings (Accumulated Deficit)USD | -388,520,000Source | -349,522,000Source | -421,096,000Source | -379,917,000Source | -339,150,000Source | -409,834,000Source | -369,994,000Source | -326,550,000Source | -397,561,000Source | -358,730,000Source | -320,889,000Source | -274,225,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 91,000Source | 149,000Source | 84,000Source | 93,000Source | 98,000Source | 85,000Source | 91,000Source | 97,000Source | 91,000Source | 90,000Source | 91,000Source | 150,000Source |
| Stockholders' Equity Attributable to ParentUSD | 1,557,000Source | -6,272,000Source | -15,866,000Source | 9,184,000Source | 2,870,000Source | -5,201,000Source | 18,123,000Source | 14,384,000Source | 6,313,000Source | 28,458,000Source | 18,881,000Source | 14,305,000Source |
| Liabilities and EquityUSD | 61,587,000Source | 53,016,000Source | 59,738,000Source | 67,537,000Source | 60,204,000Source | 69,891,000Source | 77,251,000Source | 71,837,000Source | 81,418,000Source | 86,570,000Source | 78,048,000Source | 67,855,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 16,977,000Source | 16,858,000Source | 18,218,000Source | 19,061,000Source | 14,989,000Source | 17,833,000Source | 16,536,000Source | 15,179,000Source | 17,975,000Source | 15,598,000Source | 16,967,000Source | 12,403,000Source |
| Operating Lease, Liability, CurrentUSD | 521,000Source | 559,000Source | 530,000Source | 518,000Source | 571,000Source | 527,000Source | 532,000Source | 568,000Source | 524,000Source | 545,000Source | 565,000Source | 340,000Source |
| Accounts Payable, CurrentUSD | 2,373,000Source | 2,479,000Source | 2,883,000Source | 1,741,000Source | 2,314,000Source | 3,894,000Source | 4,002,000Source | 3,357,000Source | 2,309,000Source | 2,147,000Source | 1,667,000Source | 1,534,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | — | — | — | — | — | — | — | 1,400,000Source | 1,700,000Source | 1,200,000Source |
| Other Liabilities, NoncurrentUSD | 1,559,000Source | 1,460,000Source | 1,305,000Source | 1,241,000Source | 1,528,000Source | 1,393,000Source | 1,317,000Source | 1,609,000Source | 1,477,000Source | 1,390,000Source | 1,685,000Source | 1,231,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 14,604,000Source | 14,379,000Source | 15,335,000Source | 13,987,000Source | 12,675,000Source | 13,939,000Source | 12,534,000Source | 11,822,000Source | 15,666,000Source | 13,451,000Source | 15,300,000Source | 10,869,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 41,494,000Source | 40,970,000Source | 56,081,000Source | 38,051,000Source | 40,817,000Source | 55,866,000Source | 41,275,000Source | 40,665,000Source | 55,653,000Source | 41,124,000Source | 40,515,000Source | 39,916,000Source |
| Long-term Debt, Current Maturities | — | — | — | —Source | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -12,273,000Source | -11,264,000Source | -38,831,000Source | -37,841,000Source | -46,664,000Source | -44,296,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 816,000Source | 1,044,000Source | 3,796,000Source | 4,362,000Source | 5,032,000Source | 3,989,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -593,000Source | 402,000Source | 110,000Source | 762,000Source | 3,058,000Source | 2,421,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 2,158,000Source | 1,346,000Source | 503,000Source | 2,972,000Source | 2,718,000Source | 6,073,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 1,593,000Source | 1,853,000Source | 141,000Source | 482,000Source | 11,000Source | -884,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | 52,000Source | 144,000Source | -144,000Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -11,170,000Source | -9,725,000Source | -28,219,000Source | -41,595,000Source | -40,857,000Source | -40,748,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 190,000Source | 138,000Source | 846,000Source | 4,451,000Source | -599,000Source | -1,872,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 119,000Source | 32,000Source | 448,000Source | 989,000Source | 611,000Source | 872,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 79,000Source | 177,000Source | 205,000Source | 369,000Source | 289,000Source | 157,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -298,000Source | -116,000Source | 25,750,000Source | 43,057,000Source | 46,267,000Source | 40,852,000Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | — | — | 42,420,000Source | — | — | 30,000,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -11,304,000Source | -9,837,000Source | -1,840,000Source | 5,941,000Source | 4,975,000Source | -1,912,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 29,963,000Source | 17,566,000Source | 30,624,000Source | 35,242,000Source | 39,791,000Source | 43,098,000Source | 51,095,000Source | 52,935,000Source | 46,994,000Source | 42,019,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 1,815,000Source | 1,370,000Source | 4,716,000Source | 4,071,000Source | 4,624,000Source | 3,394,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 955,000Source | 1,081,000Source | 613,000Source | 985,000Source | 816,000Source | 1,044,000Source | 3,796,000Source | 4,362,000Source | 5,032,000Source | 3,989,000Source |
| DepreciationUSD | — | — | — | — | — | — | 169,000Source | 172,000Source | 630,000Source | 632,000Source | 428,000Source | 383,000Source |
| Disposal Group, Not Discontinued Operation, Gain (Loss) on DisposalUSD | — | — | — | — | — | — | — | — | — | 7,580,000Source | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | -32,000Source | -66,000Source | -76,000Source | 35,000Source | 316,000Source | -420,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | -18,000Source | — | — | — | 12,000Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | -888,000Source | — | — | -1,228,000Source |
| General and Administrative ExpenseUSD | — | — | 3,948,000Source | 3,683,000Source | 4,061,000Source | 4,126,000Source | 4,166,000Source | 3,836,000Source | 15,694,000Source | 14,722,000Source | 14,887,000Source | 13,862,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | 60,000Source | 33,000Source | 60,000Source | 52,000Source | 230,000Source | -144,000Source | — | — |
| InterestExpenseNonoperatingUSD | — | — | 1,201,000Source | 1,344,000Source | 2,076,000Source | 1,188,000Source | 2,053,000Source | 1,219,000Source | 5,245,000Source | 5,290,000Source | — | — |
| Inventory Write-downUSD | — | — | — | — | — | — | 935,000Source | 630,000Source | 2,360,000Source | 2,955,000Source | 1,414,000Source | 1,866,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -8,603,000Source | -10,372,000Source | -11,262,000Source | -9,923,000Source | -12,273,000Source | -11,264,000Source | -38,831,000Source | -37,841,000Source | -46,664,000Source | -44,296,000Source |
| Nonoperating Income (Expense)USD | — | — | -1,049,000Source | -1,007,000Source | -1,919,000Source | -809,000Source | -1,687,000Source | -740,000Source | -4,846,000Source | -3,870,000Source | -2,589,000Source | -5,289,000Source |
| Operating ExpensesUSD | — | — | 21,523,000Source | 22,223,000Source | 23,226,000Source | 23,186,000Source | 23,046,000Source | 22,984,000Source | 88,096,000Source | 88,183,000Source | 84,187,000Source | 66,051,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 152,000Source | 337,000Source | 157,000Source | 379,000Source | 366,000Source | 479,000Source | 1,287,000Source | 1,420,000Source | 2,634,000Source | -10,000Source |
| Payments of Financing CostsUSD | — | — | — | — | — | — | — | — | 3,554,000Source | — | — | 3,460,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | 46,341,000Source | 34,400,000Source |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 40,000,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | 1,000Source | 1,000Source | 226,000Source | 127,000Source | 19,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 20,689,000Source | 18,957,000Source | 19,291,000Source | 20,197,000Source | 19,059,000Source | 18,520,000Source | 80,275,000Source | 69,300,000Source | 58,453,000Source | 41,418,000Source |
| Operating Income (Loss)USD | — | — | -7,554,000Source | -9,365,000Source | -9,283,000Source | -9,081,000Source | -10,526,000Source | -10,472,000Source | -33,755,000Source | -34,115,000Source | -44,075,000Source | -39,007,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 152,000Source | 337,000Source | 157,000Source | 379,000Source | 366,000Source | 479,000Source | 1,287,000Source | 1,420,000Source | 2,634,000Source | -10,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -8,603,000Source | -10,372,000Source | -11,202,000Source | -9,890,000Source | -12,213,000Source | -11,212,000Source | -38,601,000Source | -37,985,000Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | 60,000Source | 33,000Source | 60,000Source | 52,000Source | 230,000Source | -144,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -8,603,000Source | -10,372,000Source | -11,262,000Source | -9,923,000Source | -12,273,000Source | -11,264,000Source | -38,831,000Source | -37,841,000Source | -46,664,000Source | -44,296,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.19Source | -0.42Source | -0.2Source | -0.22Source | -0.21Source | -0.25Source | -0.83Source | -1.33Source | -2.04Source | -2.72Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.19Source | -0.42Source | -0.2Source | -0.22Source | -0.21Source | -0.25Source | -0.83Source | -1.33Source | -2.04Source | -2.72Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 45,421,795Source | 24,703,578Source | 57,414,360Source | 45,365,325Source | 57,256,518Source | 45,267,020Source | 46,947,932Source | 28,526,441Source | 22,868,663Source | 16,267,678Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 45,421,795Source | 24,703,578Source | 57,414,360Source | 45,365,325Source | 57,256,518Source | 45,267,020Source | 46,947,932Source | 28,526,441Source | 22,868,663Source | 16,267,678Source |
| Interest Expense (non-operating)USD | — | — | 1,201,000Source | 1,344,000Source | 2,076,000Source | 1,188,000Source | 2,053,000Source | 1,219,000Source | 5,245,000Source | 5,290,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Cost of Goods and Service, Excluding Depreciation, Depletion, and AmortizationUSD | — | — | 6,625,000Source | 6,004,000Source | 5,253,000Source | 5,997,000Source | 6,444,000Source | 5,913,000Source | 25,554,000Source | 22,432,000Source | 17,961,000Source | 13,570,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 86,000Source | — | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | -32,000Source | -66,000Source | -76,000Source | 35,000Source | 316,000Source | -420,000Source |
| General and Administrative ExpenseUSD | — | — | 3,948,000Source | 3,683,000Source | 4,061,000Source | 4,126,000Source | 4,166,000Source | 3,836,000Source | 15,694,000Source | 14,722,000Source | 14,887,000Source | 13,862,000Source |
| Gross ProfitUSD | — | — | 13,969,000Source | 12,858,000Source | 13,943,000Source | 14,105,000Source | 12,520,000Source | 12,512,000Source | 54,341,000Source | 46,488,000Source | 40,112,000Source | 27,044,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -39,157,000Source | — | — | — |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 5,223,000Source | 4,051,000Source |
| Nonoperating Income (Expense)USD | — | — | -1,049,000Source | -1,007,000Source | -1,919,000Source | -809,000Source | -1,687,000Source | -740,000Source | -4,846,000Source | -3,870,000Source | -2,589,000Source | -5,289,000Source |
| Operating ExpensesUSD | — | — | 21,523,000Source | 22,223,000Source | 23,226,000Source | 23,186,000Source | 23,046,000Source | 22,984,000Source | 88,096,000Source | 88,183,000Source | 84,187,000Source | 66,051,000Source |
| Research and Development ExpenseUSD | — | — | 2,348,000Source | 2,068,000Source | 2,723,000Source | 2,203,000Source | 2,343,000Source | 2,540,000Source | 9,220,000Source | 8,813,000Source | 9,619,000Source | 8,937,000Source |
| Selling and Marketing ExpenseUSD | — | — | 15,227,000Source | 16,472,000Source | 16,442,000Source | 16,857,000Source | 16,537,000Source | 16,608,000Source | 63,182,000Source | 64,648,000Source | 59,681,000Source | 43,252,000Source |
Offerings
Registration 333-299966
Filing attachments
tm2629367d2_ex4-8.htm · S-3 · 2026-11-10
Exhibit 4.8 TELA BIO, INC. INDENTURE Dated as of ___________, 20___ [ ] as Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 …
Read attachment ↗tm2629493d1_ex99-1.htm · 8-K · 2026-11-10
Exhibit 99.1 TELA Bio Reports Third Quarter 2026 Financial Results Reduced sequential operating loss by 21%, including cost of realignment MALVERN, PA, November 10, 2026 -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the third quarter ended September 30, 2026. Recent Highlights Delivered $19.0 million revenue in the third quarter of 2026; Increased…
Read attachment ↗tm2627013d1_ex99-1.htm · 8-K · 2026-10-05
Exhibit 99.1 TELA Bio Announces 510(k) Clearance for LioraTM Monofilament Scaffold for Soft Tissue Reinforcement MALVERN, PA, October 5, 2026 -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the Company's Liora Monofilament Scaffold (“Liora”) product. Liora is a fully resorbable surgical …
Read attachment ↗tm2624299d1_ex99-1.htm · 8-K · 2026-08-31
EX-99.1 2 tm2624299d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative Company to reduce annual operating expenses by $17.0 million or 18% as part of broader efficiency program MALVERN, PA, August 31, 2026 -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that Roberto Cuca, Chief Operating Of…
Read attachment ↗tm2622768d1_ex99-1.htm · 8-K · 2026-08-10
EX-99.1 2 tm2622768d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 TELA Bio Reports Second Quarter 2026 Financial Results MALVERN, PA, August 10, 2026 -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the second quarter ended June 30, 2026. Recent Highlights Announced appointment of Heather Getz as Chief Executive Officer and Director, effective August 4, 202…
Read attachment ↗tm2614218d1_ex99-1.htm · 8-K · 2026-05-12
EX-99.1 2 tm2614218d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 TELA Bio Reports First Quarter 2026 Financial Results MALVERN, PA, May 12, 2026 -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended March 31, 2026. Recent Highlights Announced strategic board refreshment plan to be effective at the conclusion of the 2026 Annual Meeting …
Read attachment ↗